Market Overview

UPDATE: Barrington Research Upgrades Perrigo to Outperform Ahead of FQ1 Results

Share:
Related PRGO
The Royalty-Amassing Strategy Of Royalty Pharma
How Have The Best And Worst Stocks Of 2016 Performed In 2017?

Barrington Research raised its rating on Perrigo (NASDAQ: PRGO) from Market Perform to Outperform on the assumption that they company will maintain its leadership in providing affordable care.

Barrington Research noted, "We recently traveled with the management of PRGO and were incredibly impressed. We took over coverage of PRGO last year and it has taken some time to understand and fully appreciate the sustainability of the growth opportunities that PRGO is exploiting. Over the past year, we have gained a much greater appreciation for the sustainability of the transition from prescription to OTC and branded to generic drugs and in our opinion, these trends are here to stay due to the realities of our economy and the ever increasing cost of healthcare. PRGO has 75% share of the OTC market and it has certainly taken time for us to appreciate that PRGO has sustainable competitive advantages."

Perrigo closed at $115.00 on Friday.

Latest Ratings for PRGO

DateFirmActionFromTo
Jul 2017Deutsche BankMaintainsBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Jun 2017RBC CapitalDowngradesSector PerformUnderperform

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Barrington ResearchAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (PRGO)

View Comments and Join the Discussion!